September 18, 2014
The FDA today approved dulaglutide as a once-weekly injection for patients with type 2 diabetes to improve glycemic control in conjunction with diet and exercise.
Dulaglutide, a glucagon-like peptide-1 receptor to be known as Trulicity (Eli Lilly), has been studied as a solo treatment and in conjunction with other therapies such as metformin, sulfonylurea and others. In the most recent study published, dulaglutide was shown comparable to liraglutide (Victoza, Novo Nordisk) in controlling HbA1c and hypoglycemia. The most common side effects were nausea, diarrhea, vomiting, abdominal pain and decreased appetite.